|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 179.70 GBX | +0.17% |
|
+3.46% | +7.43% |
| 01-14 | Davy raises IAG, cuts Jet2; RBC cuts Reckitt | AN |
| 01-05 | Spire Healthcare Group Schedules Deadline for Registering Takeover Interest | MT |
| Capitalization | 722M 971M 833M 776M 1.35B 87.65B 1.45B 8.92B 3.51B 41.93B 3.64B 3.57B 154B | P/E ratio 2025 * |
21.3x | P/E ratio 2026 * | 16.8x |
|---|---|---|---|---|---|
| Enterprise value | 1.94B 2.61B 2.24B 2.09B 3.62B 236B 3.9B 23.98B 9.43B 113B 9.79B 9.59B 413B | EV / Sales 2025 * |
1.23x | EV / Sales 2026 * | 1.16x |
| Free-Float |
65.28% | Yield 2025 * |
1.4% | Yield 2026 * | 1.69% |
Last Transcript: Spire Healthcare Group plc
| 1 day | -0.50% | ||
| 1 week | +3.69% | ||
| Current month | +7.66% | ||
| 1 month | +8.71% | ||
| 3 months | -25.70% | ||
| 6 months | -19.01% | ||
| Current year | +7.66% |
| 1 week | 169.6 |  | 185 |
| 1 month | 164 | | 185 |
| Current year | 166 | | 185 |
| 1 year | 164 | | 256.5 |
| 3 years | 164 | | 270.5 |
| 5 years | 143 | | 270.5 |
| 10 years | 51.1 | | 411 |
| Manager | Title | Age | Since |
|---|---|---|---|
Justinian Ash
CEO | Chief Executive Officer | 61 | 29/10/2017 |
Harbant Samra
DFI | Director of Finance/CFO | - | 08/05/2024 |
Lisa Grant
CTO | Chief Tech/Sci/R&D Officer | - | 28/02/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Justinian Ash
BRD | Director/Board Member | 61 | 29/10/2017 |
C. van der Merwe
BRD | Director/Board Member | 62 | 23/05/2018 |
Jenny Kay
BRD | Director/Board Member | - | 31/05/2019 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.50% | +3.69% | -24.14% | -26.31% | 971M | |
| -0.24% | -1.75% | +19.07% | +40.73% | 18.43B | |
| -0.43% | +3.64% | -7.89% | -55.02% | 15.62B | |
| -0.53% | -2.35% | +8.43% | +67.74% | 11.58B | |
| +1.56% | +1.82% | +33.32% | +89.60% | 10.21B | |
| +2.45% | -3.39% | +8.35% | +65.84% | 10.08B | |
| +2.78% | -5.13% | -20.94% | -38.84% | 9.1B | |
| -1.61% | -6.87% | -31.27% | - | 7.5B | |
| +0.21% | -3.28% | +37.13% | +216.34% | 7.61B | |
| +0.22% | +5.47% | +7.22% | -45.01% | 5.65B | |
| Average | +0.39% | -0.81% | +2.93% | +35.01% | 9.68B | |
| Weighted average by Cap. | +0.40% | -1.38% | +6.46% | +36.61% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.58B 2.13B 1.82B 1.7B 2.95B 192B 3.18B 19.53B 7.68B 91.8B 7.97B 7.81B 336B | 1.63B 2.2B 1.88B 1.75B 3.05B 198B 3.28B 20.17B 7.94B 94.84B 8.24B 8.07B 348B |
| Net income | 34.51M 46.42M 39.83M 37.08M 64.4M 4.19B 69.42M 426M 168M 2B 174M 170M 7.34B | 43.57M 58.6M 50.29M 46.82M 81.31M 5.29B 87.65M 538M 212M 2.53B 220M 215M 9.27B |
| Net Debt | 1.22B 1.64B 1.41B 1.31B 2.28B 148B 2.45B 15.06B 5.93B 70.81B 6.15B 6.02B 259B | 1.17B 1.57B 1.35B 1.26B 2.18B 142B 2.35B 14.45B 5.68B 67.94B 5.9B 5.78B 249B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/01/26 | 179.40 p | 0.00% | 628,548 |
| 14/01/26 | 179.40 p | -1.64% | 3,118,200 |
| 13/01/26 | 182.40 p | +3.64% | 4,270,773 |
| 12/01/26 | 176.00 p | +1.15% | 1,740,476 |
| 09/01/26 | 174.00 p | +0.35% | 2,130,223 |
Delayed Quote London S.E., January 15, 2026 at 03:04 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SPI Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition